References
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.
Zhou Y, He W, Guo P, et al. Development and validation of a recurrence-free survival prediction model for locally advanced esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14308-3.
Baldominos P, Barbera-Mourelle A, Barreiro O, et al. Quiescent cancer cells resist T-cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694–708. https://doi.org/10.1016/j.cell.2022.03.033.
Federico L, McGrail DJ, Bentebibel S-E, et al. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2022;33(1):42–56. https://doi.org/10.1016/j.annonc.2021.09.021.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhou, Y., Huang, Z. & Liu, Y. ASO Author Reflections: Prognosis of Esophageal Cancer After Neoadjuvant Therapy: A More Accurate Evaluation System is Needed. Ann Surg Oncol 31, 239–240 (2024). https://doi.org/10.1245/s10434-023-14363-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-14363-w